Respiratory failure and outcomes in patients with cardiovascular disease, depending on ACEi and ARBs exposure
| Patients with COVID-19 (n=412) | |||||||||
| CVD no (n=205) | CVD yes (n=207) | P value | CVD yes (n=207) | ||||||
| ACEi no (n=154) | ACEi yes (n=53) | P value | ARBs no (n=147) | ARBs yes (n=60) | P value | ||||
| PaO2/FiO2 at admission | 307.5 (180–381) | 206.5 (123–305) | <0.0001 | 203 (127–319) | 228 (113–290) | 0.62 | 201.5 (118.0–285.5) | 285.5 (135–343) | 0.01 |
| RF at admission, n (%) | 125 (61.0) | 174 (84.1) | <0.0001 | 129 (83.8) | 45 (84.9) | 0.85 | 128 (87.1) | 46 (76.7) | 0.06 |
| CPAP at admission, n (%) | 16 (7.8) | 24 (11.6) | 0.19 | 20 (13.0) | 4 (7.6) | 0.29 | 17 (11.6) | 7 (11.7) | 0.98 |
| CPAP in-hospital, n (%) | 76 (37.1) | 100 (48.3) | 0.02 | 75 (48.7) | 25 (47.2) | 0.85 | 71 (48.3) | 29 (48.3) | 1.00 |
| In-hospital mortality, n (%) | 32 (15.6) | 72 (34.8) | <0.0001 | 53 (34.4) | 19 (35.9) | 0.85 | 58 (39.5) | 14 (23.3) | 0.03 |
| Intubation, n (%) | 23 (11.2) | 13 (6.3) | 0.08 | 9 (5.8) | 4 (7.6) | 0.74 | 9 (6.1) | 4 (6.7) | 1.00 |
Data are reported as frequencies or medians (IQR).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CPAP, continuous positive airway pressure; CVD, cardiovascular disease; FiO2, fraction of inhaled oxygen; PaO2, arterial partial pressure of oxygen.